Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-06-15
2000-09-12
Schwartzman, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 245, 435375, A61K 3170, C07H 2100
Patent
active
061178470
ABSTRACT:
Compositions and methods are provided for modulating the expression of protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. The oligonucleotides are from 5 to 50 nucleotides in length and in one referred embodiment are from 12 to 18 nucleotides in length. The oligonucleotides may be chimeric oligonucleotides and in a preferred embodiment comprise at least one 2'-O-methoxyethyl modification. Pharmaceutical compositions comprising the oligonucleotides of the invention are also provided. Methods of inhibiting protein kinase C expression and methods of treating conditions associated with expression of protein kinase C using oligonucleotides of the invention are disclosed.
REFERENCES:
patent: 4511713 (1985-04-01), Miller et al.
patent: 4806463 (1989-02-01), Mattingly, III et al.
patent: 5004810 (1991-04-01), Draper
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5138045 (1992-08-01), Cook et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5218105 (1993-06-01), Cook et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5620963 (1997-04-01), Cook et al.
patent: 5681747 (1997-10-01), Boggs et al.
patent: 5703054 (1997-12-01), Bennet et al.
patent: 5744460 (1998-04-01), Muller et al.
patent: 5922686 (1999-07-01), Bennett et al.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93: 3161-3163, Apr. 1996.
Stein. Keeping the biotechnology of antisense in context. Nature Biotechnol. 17: 209, Mar. 1999.
Ahmad, et al., "Antisense Expression of Protein Kinase C.alpha.Inhibits the Growth and Tumorigenicity of Human Glioblastoma Cells", Neurosurg., 35, 1994, 904-908.
Becker et al., "Differential expression of protein kinase C and cAmp-dependent protein kinase in normal human melanocytes and malignant melanomas", Oncogene, 1990, 5(8), 1133-1139 (Abstract Only).
Bioworld Today, Apr. 29, 1994, p. 3.
Cook, "Medicinal chemistry of antisense oligonucleotides-future opportunities", Anti-Cancer Drug Des., 1991, 6, 585-607.
Sambrook, et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, vol. 2, p. 10.59.
Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle", Chem. Rev., Jun. 1990, 90(4), 543-584.
Weinstein, et al., "Cancer Prevention: Recent Progress and Future Opportunities", Cancer Res., (Suppl.) 51, 1991, 5080s-5085s.
1993 Catalog of Products for DNA Research, Glen Research, Sterling, VA, p. 21.
Bacher, et al., "Isolation and Characterization of PKC-L, a New Member of the Protein Kinase C-Related Gene Family Specifically Expressed in Lung, Skin and Heart", Molecular and Cellular Biol., 11, 1191, 126-133.
Ballester and Rosen, Fate of Immunoprecipitable Protein Kinase C in GH.sub.3 Cells Treated with Phorbol 12-Myristate 13-Acetate, Journal of Biological Chemistry, 260, 1985, 15194-15199.
Baxter, et al., "PKC-episilon is involved in granulocyte-macrophage colong-stimulating factor signal transduction: Evidence from microphysiometry and antisense oligonucleotide experiments", Biochemistry, 31, 1992, 10950-10954.
Berkowitz, et al., "Synthesis of 1,2-Dihydro-1-(2-deoxy-.beta.-D-Erythro-pentafuranosyl)-2-Oxopyrazine 4-oxide, a potent analog of deoxyuridine", J. Medicinal Chemistry, 16(2), 1973, 813-814.
Borek, et al., "Long Chain (sphingoid) Bases Inhibit Multistage Carcinogenesis in Mouse C3H/10T1/2 Cells Treated with Radiation and Phorbol 12-Myristate 13-Acetate", Proc. Natl. Acad. Sci., 88, 1991, 1953-1957.
Coussens, et al., "Multiple, Distinct Forms of Bovine and Human Protein Kinase C Suggest Diversity in Cellular Signaling Pathways", Science, 233, 1986, 859-866.
Endo, et al., "Cell Membrane Signaling as Target in Cancer Therapy: Inhibitory Effect of N,N-Dimethyl and N,N,N-Trimethyl Sphingosine Derivatives on in Vitro and in Vivo Growth of Human Tumor Cells in Nude Mice", Cancer Research, 51, 1991, 1613-1618.
Farese, et al., "Antisense DNA downregulates protein kinase C isozymes (beta and alpha) and insulin-stimulated 2- deoxyglucose uptake in rat adipocytes", Antisense, Res. Dev., 1(1), 1991, 35-42.
Finkenzeller, et al., "Sequence of Human Protein Kinase C .alpha.", Nucl. Acids Res., 18, 1990, 2183.
Gescher and Dale, "Protein Kinase C--A Novel Target for Rational Anti-Cancer Drug Design?" Anti-Cancer Drug Design, 4, 1989, 93-105.
Godson, et al., "Inhibition of Expression of Protein Kinase C .alpha. By Antisense cDNA Inhibits Phorbol Ester-Mediated Arachidonate Release", J. Biol. Chem., 268, 1993, 11946-11950.
Hackh's Chemical Dictionary, Grant, et al., Ed., McGraw-Hill Book Company, New York, p. 312.
Hegemann and Mahrle, Pharmacology of the Skin, H. Mukhtar, Ed., pp. 357-368, CRC Press, Boca Raton, FL, 1992.
Hidaka and Hagiwara, "Pharmacology of the Isoquinoline Sulfonamide Protein Kinase C Inhibitors", Trends in Pharm Sci., 8, 1987, 162-164.
Kawasaki, A.M. et al., "Synthesis and Biophysical Studies of 2'-dRibo-2'-F Modified Oligonucleotides", Conf. On Nucleic Acid Therapeutics, Clearwater, FL, Jan. 13-16, 1991, 10 pages.
Krug, et al., "Evidence for Increased Synthesis as well as Increased Degradation of Protein Kinase C After Treatment of Human Osteosarcoma Cells with Phorbol Ester", J. Biol. Chem., 262, 1987, 11852-11856.
Kubo, et al., "Primary Structures of Human Protein Kinase C.beta.I and .beta.II Differ Only in their C-Terminal Sequences", FEBS Lett. 223, 1987, 138-142.
Maier, et al., "An oligomer targeted against protein kinase C alpha prevents interleukin-1 alpha induction of cyclooxygenase expression in human endothelial cells", Exp. Cell. Res., 205(1), 1993, 52-58.
Marcus-Sekura, "Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression", Analytical Biochemistry, 172, 1988, 289-295.
Nielsen, et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide", Science, 254, 1991, 1497-1500.
Nishizuka, "The Molecular Heterogeneity of Protein Kinase C and Its Implications for Cellular Regulation", Nature, 334, 1988, 661-665.
Osada, et al., "A Phorbol Ester Receptor/Protein Kinase nPKC.eta., a New Member of the Protein Kinase C Family Predominantly Expressed in Lung and Skin", J. Biol. Chem., 265, 1990, 22434-22440.
Parker, et al., "The Complete Primary Structure of Protein Kinase C-the Major Phorbol Ester Receptor", Science, 233, 1986, 853-866.
Rothenberg, et al., "Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications", J. Natl. Cancer Inst., 1989, 81, 1539-1544.
Sakanoue, et al., "Protein Kinase C Activity as Marker for Colorectal Cancer", Int. J. Cancer, 48, 1991, 803-806.
Standaert, et al., 1991, J. Cellular Biochem., (Keystone Symposia on Molecular and Cellular Biology), Jan. 18-25), Suppl. 15B, p. 26, abstract CA 211.
Watson, et al., 1987, in: Molecular Biology of the Gene, Fourth Edition, Benjamin/Cummings Publishing Company, Menlo Park, CA p. 241.
Webster's II New Riverside University Dictionary, Soulkkanov, et al., Eds., 1984, Houghton Mifflin Company, Boston, MA, p. 68.
Young, et al., "Down-Regulation of Protein Kinase C is Due to an Increased Rate of Degradation", Biochem. J, 244, 1987, 775-779.
Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents", Pharmaceutical Res., 5, 1988, 539-549.
Brandt, et al., "Distinct Patterns of Expression of Different Protein Kinase C mRNA's in Rat Tissue", Cell, 49, 57-63.
Simons, et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo", Nature, 359, 1992, 67-70.
Greenberg in Current Protocols in Molecular Biology, Ausubel, et al., Eds., John Wiley & Sons, NY, 1987.
Berge, S.M. et al., "Ph
Bennett C. Frank
Dean Nicholas M.
ISIS Pharmaceuticals Inc.
Larson Thomas G.
Schwartzman Robert A.
LandOfFree
Oligonucleotides for enhanced modulation of protein kinase C exp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides for enhanced modulation of protein kinase C exp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides for enhanced modulation of protein kinase C exp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96209